Mylan president Rajiv Malik has been named in an expanded federal lawsuit filed by attorneys general in nearly every state, including Pennsylvania, that accuses Mylan and more than a dozen other drugmakers of conspiring to fix prices for generic drugs.
The amended complaint, which state officials are asking federal court for permission to file, also names Satish Mehta, CEO of the India-based drugmaker Emcure Pharmaceuticals, the parent company of Heritage Pharmaceuticals in New Jersey.
Mr. Malik and Mr. Mehta would be the first senior executives sued in the case.
“These conspiracies were part of a much broader, overarching industry code of conduct that enabled the [drugmakers] to divvy up the market for specific generic drugs in accordance with an established, agreed-upon understanding for assigning each competitor their share of the market,” said Connecticut Attorney General George Jepsen, who is leading the antitrust investigation, in a statement.
The original lawsuit, filed in December 2016 in Connecticut and moved to Philadelphia in August, named Mylan, Heritage Pharmaceuticals and four other drugmakers, accusing them of conspiring to fix prices for two drugs. The new complaint expands the number of generic drug companies to 18 and the number of drugs at issue to 15.
The U.S. Department of Justice also is conducting a probe.
“Mylan has deep faith in the integrity of its president, Rajiv Malik, and stands behind him fully,” Mylan, which is run from executive offices in Cecil, said in a statement Tuesday.
“We have been investigating these allegations thoroughly and have found no evidence of price fixing on the part of Mylan or its employees,” the company said, adding that it would “defend this case vigorously.”
The complaint alleges that the misconduct was conceived and carried out by senior drug company executives and their subordinate marketing and sales executives.
The suit also contends that the companies knews their conduct was illegal and made efforts to avoid communicating with each other in writing, or in some instances, to delete written electronic communications after becoming aware of the investigation.
“The allegations of our complaint are shocking, and the depth and breadth of the conspiracies alleged are mind-blowing,” Mr. Jepsen said.
“The generic drug market was conceived as a way to help bring down the cost of prescription medications for American consumers,” he said. “For years, though, those savings have not been realized, and instead, the prices of many generic drugs have skyrocketed.”
Mr. Jepsen alleged illegal collusion was so pervasive “that it essentially eliminated competition from the market” and artificially raised prices for the 15 named drugs, including the antibiotic doxycycline, the high blood pressure medication verapamil, the diabetes drug glyburide-metformin, and leflunomide, which treats rheumatoid arthritis.
Mr. Jepsen said investigators expect to uncover additional evidence and expand the claims to include more companies and drugs in the future.
Spiraling drug prices have triggered a public backlash and intense criticism on Capitol Hill in recent years.
Mylan landed in lawmakers’ crosshairs a year ago amid cries of price-gouging for upping the list price of its EpiPen emergency allergy shot from around $100 a two-pack in 2009, to more than $600.
Mr. Malik has served as Mylan’s president since 2012, succeeding Heather Bresch, who was appointed CEO. He joined the company in 2007 when Mylan acquired a controlling stake in India-based Matrix Laboratories, where Mr. Malik was CEO.
Mr. Malik and Mr. Mehta “were directly involved in conceiving an illegal agreement and taking affirmative steps to ensure it was executed by their subordinates,” Mr. Jepsen’s office said.
Mylan’s shares closed Tuesday at $35.71, down $2.53 or 6.6 percent.
Patricia Sabatini: PSabatini@post-gazette.com; 412-263-3066.




Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.